Barclays’s Acceleron Pharma XLRN Stock Holding History

Barclays’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-79,800	Closed	-$4.23M	–	6635
2019 Q4	$4.23M	Buy	79,800 +65,200	+447%	+$2.97M	﹤0.01%	2189
2019 Q3	$577K	Hold	14,600	–	–	﹤0.01%	4131
2019 Q2	$600K	Buy	14,600 +13,800	+1,725%	+$571K	﹤0.01%	4160
2019 Q1	$37K	Buy	+800	New	+$35.1K	﹤0.01%	6076

Barclays's XLRN Position: Q4 2021 in Review

Barclays sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 111,461 shares — an estimated $19.2M sold.

Barclays first reported a position in XLRN in Q4 2013 and held it in 32 quarters. The position peaked at $19.2M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Barclays reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Barclays sold 111,461 Acceleron Pharma shares in Q4 2021, an estimated $19.2M.
Barclays first reported a position in Acceleron Pharma in Q4 2013 and held it in 32 quarters.
Barclays's Acceleron Pharma position peaked at $19.2M in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.